A recurrent splicing variant without c-ABL Exon 7 in Imatinib-resistant patients

Leukemia Research

Volumn 32, Issue 3, 2008, Pages 508-510

  Curvo, Raphael P M ^a   Zalcberg, Ilana R ^b   Scholl, Vanesa ^b   Pires, Virginia ^b   Moellmann Coelho, Arthur ^b   Moreira, Miguel A M ^b  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO NACIONAL DE CÂNCER   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; AMINO ACID; BCR ABL PROTEIN; COMPLEMENTARY DNA; IMATINIB; NUCLEOTIDE; RNA; TUMOR MARKER;

AMINO ACID SUBSTITUTION; CANCER RECURRENCE; CATALYSIS; CELL HETEROGENEITY; CHRONIC MYELOID LEUKEMIA; DNA SYNTHESIS; DRUG EFFICACY; ENZYME ACTIVITY; EXON; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC CODE; GENETIC TRANSCRIPTION; HUMAN; LETTER; MOLECULAR CLONING; MOLECULAR DOCKING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; RNA ISOLATION; RNA SPLICING;

ALTERNATIVE SPLICING; DRUG RESISTANCE, NEOPLASM; GENES, ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PYRIMIDINES;

EID: 39749147983     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.04.018     Document Type: Letter

References (10)

1. Daley G.Q., Van Etten R.A., and Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210 (bcr/abl) gene of the Philadelphia chromosome. Science 247 (1990) 824-830
2. Deininger M.W., Goldman J.M., Lydon N., and Melo J.V. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90 (1997) 3691-3698
3. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293 (2001) 876-880
4. Kreuzer K.A., Le Coutre P., Landt O., Na I.K., Schwarz M., Schultheis K., et al. Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann Hematol 82 (2003) 284-289
5. Marin D., Kaeda J., Szydlo R., Saunders S., Fleming A., Howard J., et al. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse. Leukemia 19 (2005) 507-512
6. Gruber F.X., Hjorth-Hasen H., Mikkola I., Stenke L., and Johansen T. A novel BCR-ABL splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib. Leukemia 20 (2006) 2057-2060
7. Wang Z., Lo H.S., Yang H., Gere S., Hu Y., Buetow K.H., et al. Computational analysis and experimental validation of tumor-associated alternative RNA splicing in human cancer. Cancer Res 63 (2003) 655-657
8. Kirschbaum-Slager N., Lopes G.M., Galante P.A., Riggins G.J., and de Souza S.J. Splicing factors are differentially expressed in tumors. Genet Mol Res 30 (2004) 512-520
9. Branford S., Rudzki Z., Walsh S., Grigg A., Arthur C., Taylor K., et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99 (2002) 3472-3475
10. Hochhaus A., Kreil S., Corbin A.S., La Rosee P., Muller M.C., Lahaye T., et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 16 (2002) 2190-2196